Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam
· Delayed Price · Currency is VND 69,200
0.00 (0.00%)
At close: Mar 6, 2026
Ha Tay Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,402,040 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | Upgrade
|
| Revenue Growth (YoY) | 15.13% | 4.35% | 8.81% | 14.17% | -19.79% | Upgrade
|
| Cost of Revenue | 2,192,851 | 1,866,534 | 1,795,972 | 1,650,138 | 1,455,342 | Upgrade
|
| Gross Profit | 209,189 | 219,818 | 203,331 | 187,256 | 154,022 | Upgrade
|
| Selling, General & Admin | 168,478 | 143,306 | 104,115 | 84,806 | 91,953 | Upgrade
|
| Operating Expenses | 168,478 | 143,306 | 104,115 | 84,806 | 91,953 | Upgrade
|
| Operating Income | 40,711 | 76,513 | 99,216 | 102,450 | 62,070 | Upgrade
|
| Interest Expense | -13,056 | -13,449 | -20,099 | -14,304 | -13,993 | Upgrade
|
| Interest & Investment Income | 30,213 | 19,544 | 19,614 | 25,120 | 29,451 | Upgrade
|
| Earnings From Equity Investments | 7,389 | 6,756 | 4,171 | 2,971 | 1,996 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 277.88 | Upgrade
|
| Other Non Operating Income (Expenses) | 8,053 | 5,858 | 7,442 | 6,986 | 9,788 | Upgrade
|
| EBT Excluding Unusual Items | 73,309 | 95,222 | 110,344 | 123,224 | 89,590 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -77.14 | Upgrade
|
| Pretax Income | 73,309 | 95,222 | 110,344 | 123,224 | 89,513 | Upgrade
|
| Income Tax Expense | 14,269 | 20,028 | 21,382 | 24,259 | 18,123 | Upgrade
|
| Earnings From Continuing Operations | 59,040 | 75,194 | 88,961 | 98,964 | 71,390 | Upgrade
|
| Minority Interest in Earnings | -5,384 | -3,422 | -3,906 | -3,753 | -3,444 | Upgrade
|
| Net Income | 53,657 | 71,772 | 85,056 | 95,211 | 67,946 | Upgrade
|
| Net Income to Common | 53,657 | 71,772 | 85,056 | 95,211 | 67,946 | Upgrade
|
| Net Income Growth | -25.24% | -15.62% | -10.67% | 40.13% | -26.18% | Upgrade
|
| Shares Outstanding (Basic) | 91 | 91 | 56 | - | 81 | Upgrade
|
| Shares Outstanding (Diluted) | 91 | 91 | 56 | - | 81 | Upgrade
|
| Shares Change (YoY) | - | 62.83% | - | - | -0.77% | Upgrade
|
| EPS (Basic) | 592.41 | 792.41 | 1529.08 | - | 841.84 | Upgrade
|
| EPS (Diluted) | 592.41 | 792.41 | 1529.08 | - | 841.84 | Upgrade
|
| EPS Growth | -25.24% | -48.18% | - | - | -25.61% | Upgrade
|
| Free Cash Flow | 176,961 | -115,173 | -95,725 | -286,024 | -83,817 | Upgrade
|
| Free Cash Flow Per Share | 1953.77 | -1271.59 | -1720.88 | - | -1038.49 | Upgrade
|
| Dividend Per Share | - | - | - | - | 324.675 | Upgrade
|
| Gross Margin | 8.71% | 10.54% | 10.17% | 10.19% | 9.57% | Upgrade
|
| Operating Margin | 1.70% | 3.67% | 4.96% | 5.58% | 3.86% | Upgrade
|
| Profit Margin | 2.23% | 3.44% | 4.25% | 5.18% | 4.22% | Upgrade
|
| Free Cash Flow Margin | 7.37% | -5.52% | -4.79% | -15.57% | -5.21% | Upgrade
|
| EBITDA | 64,854 | 96,993 | 116,294 | 119,898 | 78,504 | Upgrade
|
| EBITDA Margin | 2.70% | 4.65% | 5.82% | 6.53% | 4.88% | Upgrade
|
| D&A For EBITDA | 24,143 | 20,481 | 17,078 | 17,448 | 16,435 | Upgrade
|
| EBIT | 40,711 | 76,513 | 99,216 | 102,450 | 62,070 | Upgrade
|
| EBIT Margin | 1.70% | 3.67% | 4.96% | 5.58% | 3.86% | Upgrade
|
| Effective Tax Rate | 19.46% | 21.03% | 19.38% | 19.69% | 20.25% | Upgrade
|
| Revenue as Reported | 2,402,040 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.